BioSpace News Archive

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that Executive Chairman, Eugene Williams will participate on an executive panel at the Fall Investor Summit being held today at noon at the JW Marriot Essex House

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

Vice President of Firm’s Physician Leader Search Team Receives Prestigious Designation and Board Certification in Healthcare Management

Harmony Biosciences, LLC (Harmony) announced today it will present clinical data on the efficacy and safety of WAKIX® (pitolisant) at the World Sleep 2019 meeting in Vancouver, Canada from September 20-25, 2019

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 10:30am ET in New York, NY.

Medality Medical LLC (“Medality” or the “Company”), a U.S.-based medical technology company, announced that it has received Institutional Review Board (IRB) approval from the University of Texas Health Science Center at San Antonio to commence human trials.

The Arizona Bioindustry Association (AZBio) today announced that Regenesis Biomedical, Inc. has been named the Arizona Bioscience Company of the Year and will be honored on October 2, 2019, at the AZBio Awards.

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the company’s key activities at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco.

Sept. 16, 2019 07:00 UTC PASADENA, Calif.--( BUSINESS WIRE )-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE. The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3 (ANGPTL3), and both candidates reduced tr

At the 18th Human Proteome Organization World Congress, Bruker announced the release of the diaPASEF workflow, a novel data-independent acquisition method on the timsTOF Pro platform.